Q1 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Novartis pipeline in registration Solid Tumors Code Name Mechanism Indication(s) VDT482 tislelizumab PD1 inhibitor 2L ESCC Non-small cell lung cancer Immunology Code Name Mechanism AIN457 CosentyxⓇ IL17A inhibitor IGE025 XolairⓇ IgE inhibitor 1. Approved in US. Indication(s) Hidradenitis suppurativa Psoriatic arthritis (IV formulation) Axial SpA (IV formulation) Auto-injector Appendix Innovation: Clinical trials Cardiovascular Code LCZ696 Name Entresto® Mechanism Angiotensin receptor/neprilysin inhibitor References Abbreviations INNOVATION 1 lead indication Lead indication Indication(s) Chronic heart failure, pediatrics1 38 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation